These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 25936644)

  • 1. LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response.
    Li F; Han X; Li F; Wang R; Wang H; Gao Y; Wang X; Fang Z; Zhang W; Yao S; Tong X; Wang Y; Feng Y; Sun Y; Li Y; Wong KK; Zhai Q; Chen H; Ji H
    Cancer Cell; 2015 May; 27(5):698-711. PubMed ID: 25936644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LKB1 Inactivation Promotes ROS-Induced Plasticity in NSCLC.
    Cancer Discov; 2015 Jul; 5(7):OF22. PubMed ID: 25977220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin.
    Zhang W; Gao Y; Li F; Tong X; Ren Y; Han X; Yao S; Long F; Yang Z; Fan H; Zhang L; Ji H
    Cancer Res; 2015 Nov; 75(21):4450-7. PubMed ID: 26363011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative stress-triggered Wnt signaling perturbation characterizes the tipping point of lung adeno-to-squamous transdifferentiation.
    Fang Z; Han X; Chen Y; Tong X; Xue Y; Yao S; Tang S; Pan Y; Sun Y; Wang X; Jin Y; Chen H; Hu L; Hui L; Li L; Chen L; Ji H
    Signal Transduct Target Ther; 2023 Jan; 8(1):16. PubMed ID: 36627278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LKB1 inactivation sensitizes non-small cell lung cancer to pharmacological aggravation of ER stress.
    Inge LJ; Friel JM; Richer AL; Fowler AJ; Whitsett T; Smith MA; Tran NL; Bremner RM
    Cancer Lett; 2014 Oct; 352(2):187-95. PubMed ID: 25011082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.
    Chen Z; Li JL; Lin S; Cao C; Gimbrone NT; Yang R; Fu DA; Carper MB; Haura EB; Schabath MB; Lu J; Amelio AL; Cress WD; Kaye FJ; Wu L
    J Clin Invest; 2016 Jun; 126(6):2267-79. PubMed ID: 27140397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation.
    Leung EL; Fan XX; Wong MP; Jiang ZH; Liu ZQ; Yao XJ; Lu LL; Zhou YL; Yau LF; Tin VP; Liu L
    Antioxid Redox Signal; 2016 Feb; 24(5):263-79. PubMed ID: 26528827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma.
    Han X; Li F; Fang Z; Gao Y; Li F; Fang R; Yao S; Sun Y; Li L; Zhang W; Ma H; Xiao Q; Ge G; Fang J; Wang H; Zhang L; Wong KK; Chen H; Hou Y; Ji H
    Nat Commun; 2014; 5():3261. PubMed ID: 24531128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose-6-phosphate dehydrogenase maintains redox homeostasis and biosynthesis in LKB1-deficient KRAS-driven lung cancer.
    Lan T; Arastu S; Lam J; Kim H; Wang W; Wang S; Bhatt V; Lopes EC; Hu Z; Sun M; Luo X; Ghergurovich JM; Su X; Rabinowitz JD; White E; Guo JY
    Nat Commun; 2024 Jul; 15(1):5857. PubMed ID: 38997257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.
    Kim J; Hu Z; Cai L; Li K; Choi E; Faubert B; Bezwada D; Rodriguez-Canales J; Villalobos P; Lin YF; Ni M; Huffman KE; Girard L; Byers LA; Unsal-Kacmaz K; Peña CG; Heymach JV; Wauters E; Vansteenkiste J; Castrillon DH; Chen BPC; Wistuba I; Lambrechts D; Xu J; Minna JD; DeBerardinis RJ
    Nature; 2017 Jun; 546(7656):168-172. PubMed ID: 28538732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin.
    Shackelford DB; Abt E; Gerken L; Vasquez DS; Seki A; Leblanc M; Wei L; Fishbein MC; Czernin J; Mischel PS; Shaw RJ
    Cancer Cell; 2013 Feb; 23(2):143-58. PubMed ID: 23352126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
    Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
    Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced expression of liver kinase B1 and Beclin1 is associated with the poor survival of patients with non-small cell lung cancer.
    Jiang L; Liang X; Liu M; Wang W; Ma J; Guo Q; Han L; Yang C; Nan K
    Oncol Rep; 2014 Nov; 32(5):1931-8. PubMed ID: 25175672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1.
    Ou W; Ye S; Yang W; Wang Y; Ma Q; Yu C; Shi H; Yuan Z; Zhong G; Ren J; Zhu W; Wei Y
    Cancer Gene Ther; 2012 Jul; 19(7):489-98. PubMed ID: 22576699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LKB1 promotes metabolic flexibility in response to energy stress.
    Parker SJ; Svensson RU; Divakaruni AS; Lefebvre AE; Murphy AN; Shaw RJ; Metallo CM
    Metab Eng; 2017 Sep; 43(Pt B):208-217. PubMed ID: 28034771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Han S; Khuri FR; Roman J
    Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FBXO22 mediates polyubiquitination and inactivation of LKB1 to promote lung cancer cell growth.
    Zhu XN; He P; Zhang L; Yang S; Zhang HL; Zhu D; Liu MD; Yu Y
    Cell Death Dis; 2019 Jun; 10(7):486. PubMed ID: 31217475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
    Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
    Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence, Mechanism, and Clinical Relevance of the Transdifferentiation from Lung Adenocarcinoma to Squamous Cell Carcinoma.
    Hou S; Zhou S; Qin Z; Yang L; Han X; Yao S; Ji H
    Am J Pathol; 2017 May; 187(5):954-962. PubMed ID: 28284717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.